Without insurance, both Wegovy and Zepbound carry list prices above a thousand dollars a month, but almost no cash payer pays that. The real uninsured cost is set by each maker’s self-pay program, which drops the figure well below list, and by the dose you are on. Zepbound is sometimes the cheaper of the two at cash pricing, though the gap shifts by dose and by promotion. So how much is Wegovy without insurance in practice? Usually a few hundred dollars a month, not the sticker.
Why is the list price the wrong number to compare?
List price is the figure the manufacturer publishes before any discount, and it is close to meaningless for an individual buying without coverage. Both Novo Nordisk, which makes Wegovy, and Eli Lilly, which makes Zepbound, now run direct cash programs that sell certain doses far below list. Those programs exist precisely because the sticker was pricing people out. Comparing the two brands by list price tells you almost nothing about what either will cost you next month.
The starting doses tend to be priced lower than the higher maintenance doses, which matters because most people move up over time. Semaglutide, the active molecule in Wegovy, is titrated in steps, as the Wegovy prescribing information lays out, and the same escalation pattern appears with the diabetes version described in the Ozempic label. A cash price quoted at the lowest dose is not the price you settle into.
What are the routes to a cash price?
| Route | What sets the number | Main limitation |
|---|---|---|
| List price | Manufacturer sticker before discount | Almost nobody pays it |
| Manufacturer savings card | Commercial insurance status | Excludes uninsured and government-insured |
| Manufacturer self-pay | Fixed cash price, often by dose | Refill-timing and enrollment conditions |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
Why won’t a savings card help someone uninsured?
This trips people up constantly. The largest advertised reductions come from commercial copay cards, and those cards assume you already carry commercial insurance that covers the drug. The card only trims the leftover copay. Someone with no coverage, or with Medicare or Medicaid, is usually excluded outright. If you are uninsured, the copay card is not your route, and treating its headline figure as your price leads to a rude surprise at the counter.
How do the two self-pay programs stack up?
Both makers sell single-dose vials directly to cash patients at set monthly prices. The vials are the same active medication as the pen versions, just packaged for the self-pay channel. Pricing tends to cluster in the few-hundred-dollars-a-month range for the lower doses, with higher doses costing more. Which brand is cheaper for a given person depends on the specific dose and whatever promotion is live that quarter, so the comparison has to be done at the dose level rather than brand to brand.
These programs also carry conditions worth reading before you commit. Refill timing is often restricted, meaning you cannot stockpile, and enrollment can lapse if a payment or a prescription window is missed. The sustainable monthly figure, the one you will actually pay at your target dose for a year, matters far more than the introductory price on the first fill.
Where does compounded medication sit for cash payers?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that produced the brand trial evidence. The FDA has documented safety concerns tied to some sources of these products, which the agency covers in its notice on medications containing semaglutide. That distinction is real, not a formality.
What compounded routes offer is a predictable monthly cash figure with no insurance involved. Supervised telehealth practices such as Wegovy cash price publish flat monthly pricing for this reason, alongside larger named services like Ro, Hims and Hers, and Henry Meds, with prescribing handled by a licensed clinician rather than sold as a product off a shelf. LillyDirect and NovoCare are the manufacturer-run self-pay routes for the brands themselves. The honest framing is that compounded medication trades regulatory assurance for cost predictability, and whether that trade is reasonable belongs with a prescriber who knows the case.
Does the cheaper option still deliver the results from the trials?
This is the question people skip, and it is the one that should shape the decision. The weight-loss evidence for semaglutide comes from named, controlled trials: STEP 3 tested it alongside intensive behavioral therapy in the STEP 3 randomized clinical trial, STEP 4 studied what happens to weight when treatment continues versus stops in the STEP 4 trial, and STEP 8 compared it head to head against daily liraglutide in the STEP 8 trial. Those results were generated with the approved product, not with a compounded preparation.
The trials also show that stopping tends to reverse the benefit. A STEP 1 extension tracked meaningful weight regain and a partial return of cardiometabolic changes after withdrawal. Whatever route you choose on price, it needs to be one you can sustain, because the medication works while it is taken and loosens its grip when it stops. Current practice guidance treats these drugs as long-term therapy, a point reinforced in the 2025 obesity pharmacotherapy update, which builds on evolving definitions of clinical obesity.
Key takeaways
- List price rarely reflects what an uninsured person actually pays for either drug.
- Savings cards mostly exclude uninsured and government-insured patients.
- Manufacturer self-pay vials and compounded routes are what cash payers actually compare.
- Compare at the specific dose, since prices climb as the dose is titrated up.
- Choose a price you can hold for a year, because stopping tends to reverse the results.
Frequently asked questions
How much is Wegovy without insurance?
The list price sits above a thousand dollars a month, but few uninsured people pay that. The manufacturer self-pay program lowers the figure substantially, and the actual number depends on which route you use rather than the sticker.
Is Zepbound cheaper than Wegovy for cash payers?
It can be, depending on the self-pay vial pricing each maker offers and the dose. The difference is not fixed, so a cash price should be confirmed for the specific dose rather than assumed from list prices.
Do savings cards help if I have no insurance?
Generally no. Commercial copay cards assume existing commercial coverage and exclude uninsured and government-insured patients. Manufacturer self-pay programs are the route built for people paying cash.
Is compounded semaglutide the same as Wegovy?
No. It is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not gone through the approval process behind the published trial evidence.
What should uninsured patients check before comparing prices?
The current self-pay price for the specific dose from each maker, plus whether refill-timing conditions apply. A brand comparison only makes sense once both numbers are for the same route and the same strength.
Sources
- STEP 4 Randomized Clinical Trial: https://pubmed.ncbi.nlm.nih.gov/33755728/
- STEP 8 Randomized Clinical Trial: https://pubmed.ncbi.nlm.nih.gov/35015037/
- STEP 3 Randomized Clinical Trial: https://pubmed.ncbi.nlm.nih.gov/33625476/
- Weight regain after withdrawal of semaglutide, STEP 1 extension: https://pubmed.ncbi.nlm.nih.gov/35441470/
- DailyMed, WEGOVY prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- DailyMed, OZEMPIC prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OZEMPIC
- FDA, Medications Containing Semaglutide: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-for-type-2-diabetes-or-weight-loss
- Pharmacotherapy for obesity management in adults, 2025 update: https://pubmed.ncbi.nlm.nih.gov/40789597/
- Definition and diagnostic criteria of clinical obesity: https://pubmed.ncbi.nlm.nih.gov/39824205/
